Cargando…
Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496603/ https://www.ncbi.nlm.nih.gov/pubmed/33978823 http://dx.doi.org/10.1007/s00277-021-04545-5 |
| _version_ | 1784579786972069888 |
|---|---|
| author | Heuser, Michael Smith, B. Douglas Fiedler, Walter Sekeres, Mikkael A. Montesinos, Pau Leber, Brian Merchant, Akil Papayannidis, Cristina Pérez-Simón, José A. Hoang, Caroline J. O’Brien, Thomas Ma, Weidong Wendy Zeremski, Mirjana O’Connell, Ashleigh Chan, Geoffrey Cortes, Jorge E. |
| author_facet | Heuser, Michael Smith, B. Douglas Fiedler, Walter Sekeres, Mikkael A. Montesinos, Pau Leber, Brian Merchant, Akil Papayannidis, Cristina Pérez-Simón, José A. Hoang, Caroline J. O’Brien, Thomas Ma, Weidong Wendy Zeremski, Mirjana O’Connell, Ashleigh Chan, Geoffrey Cortes, Jorge E. |
| author_sort | Heuser, Michael |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8496603 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84966032021-10-19 Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial Heuser, Michael Smith, B. Douglas Fiedler, Walter Sekeres, Mikkael A. Montesinos, Pau Leber, Brian Merchant, Akil Papayannidis, Cristina Pérez-Simón, José A. Hoang, Caroline J. O’Brien, Thomas Ma, Weidong Wendy Zeremski, Mirjana O’Connell, Ashleigh Chan, Geoffrey Cortes, Jorge E. Ann Hematol Correction Springer Berlin Heidelberg 2021-05-12 2021 /pmc/articles/PMC8496603/ /pubmed/33978823 http://dx.doi.org/10.1007/s00277-021-04545-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Heuser, Michael Smith, B. Douglas Fiedler, Walter Sekeres, Mikkael A. Montesinos, Pau Leber, Brian Merchant, Akil Papayannidis, Cristina Pérez-Simón, José A. Hoang, Caroline J. O’Brien, Thomas Ma, Weidong Wendy Zeremski, Mirjana O’Connell, Ashleigh Chan, Geoffrey Cortes, Jorge E. Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial |
| title | Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial |
| title_full | Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial |
| title_fullStr | Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial |
| title_full_unstemmed | Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial |
| title_short | Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial |
| title_sort | correction to: clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase ii randomized trial |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496603/ https://www.ncbi.nlm.nih.gov/pubmed/33978823 http://dx.doi.org/10.1007/s00277-021-04545-5 |
| work_keys_str_mv | AT heusermichael correctiontoclinicalbenefitofglasdegibpluslowdosecytarabineinpatientswithdenovoandsecondaryacutemyeloidleukemialongtermanalysisofaphaseiirandomizedtrial AT smithbdouglas correctiontoclinicalbenefitofglasdegibpluslowdosecytarabineinpatientswithdenovoandsecondaryacutemyeloidleukemialongtermanalysisofaphaseiirandomizedtrial AT fiedlerwalter correctiontoclinicalbenefitofglasdegibpluslowdosecytarabineinpatientswithdenovoandsecondaryacutemyeloidleukemialongtermanalysisofaphaseiirandomizedtrial AT sekeresmikkaela correctiontoclinicalbenefitofglasdegibpluslowdosecytarabineinpatientswithdenovoandsecondaryacutemyeloidleukemialongtermanalysisofaphaseiirandomizedtrial AT montesinospau correctiontoclinicalbenefitofglasdegibpluslowdosecytarabineinpatientswithdenovoandsecondaryacutemyeloidleukemialongtermanalysisofaphaseiirandomizedtrial AT leberbrian correctiontoclinicalbenefitofglasdegibpluslowdosecytarabineinpatientswithdenovoandsecondaryacutemyeloidleukemialongtermanalysisofaphaseiirandomizedtrial AT merchantakil correctiontoclinicalbenefitofglasdegibpluslowdosecytarabineinpatientswithdenovoandsecondaryacutemyeloidleukemialongtermanalysisofaphaseiirandomizedtrial AT papayannidiscristina correctiontoclinicalbenefitofglasdegibpluslowdosecytarabineinpatientswithdenovoandsecondaryacutemyeloidleukemialongtermanalysisofaphaseiirandomizedtrial AT perezsimonjosea correctiontoclinicalbenefitofglasdegibpluslowdosecytarabineinpatientswithdenovoandsecondaryacutemyeloidleukemialongtermanalysisofaphaseiirandomizedtrial AT hoangcarolinej correctiontoclinicalbenefitofglasdegibpluslowdosecytarabineinpatientswithdenovoandsecondaryacutemyeloidleukemialongtermanalysisofaphaseiirandomizedtrial AT obrienthomas correctiontoclinicalbenefitofglasdegibpluslowdosecytarabineinpatientswithdenovoandsecondaryacutemyeloidleukemialongtermanalysisofaphaseiirandomizedtrial AT maweidongwendy correctiontoclinicalbenefitofglasdegibpluslowdosecytarabineinpatientswithdenovoandsecondaryacutemyeloidleukemialongtermanalysisofaphaseiirandomizedtrial AT zeremskimirjana correctiontoclinicalbenefitofglasdegibpluslowdosecytarabineinpatientswithdenovoandsecondaryacutemyeloidleukemialongtermanalysisofaphaseiirandomizedtrial AT oconnellashleigh correctiontoclinicalbenefitofglasdegibpluslowdosecytarabineinpatientswithdenovoandsecondaryacutemyeloidleukemialongtermanalysisofaphaseiirandomizedtrial AT changeoffrey correctiontoclinicalbenefitofglasdegibpluslowdosecytarabineinpatientswithdenovoandsecondaryacutemyeloidleukemialongtermanalysisofaphaseiirandomizedtrial AT cortesjorgee correctiontoclinicalbenefitofglasdegibpluslowdosecytarabineinpatientswithdenovoandsecondaryacutemyeloidleukemialongtermanalysisofaphaseiirandomizedtrial |